Expert Insights

At the 2022 San Antonio Breast Cancer Symposium, Joseph Sparano, MD, discusses the efficacy of endocrine therapy alone for patients with ER-positive, HER2-negative, lymph node-negative breast cancer.

Michael Hall, MD, reviews his presentation from the 2022 Great Debates & Updates in Gastrointestinal Malignancies virtual meeting, on genetic testing for gastrointestinal cancers.

At the 2022 Great Debates & Updates in Gastrointestinal Malignancies virtual meeting, Gary Deng, MD, discusses modes of complementary medicine that patients with gastrointestinal cancers may be curious about.

Srdan Verstovsek, MD, presents data on real-world outcomes of the use of ruxolitinib in patients with myelofibrosis who had anemia or thrombocytopenia at the ASH 2022 Meeting in New Orleans, LA.

Srikala Sridhar, MD, shares insights from a study investigating how metastatic hormone sensitive prostate cancer care has changed during the COVID-19 pandemic.

Francesco Passamonti, MD, presents findings from a study on the combination of navitoclax and ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis at the 2022 ASH Annual Meeting & Exposition.

Ryan Jacobs, MD, discusses 5-year follow-up results from the CAPTIVATE study, which explored long-term outcomes after undetectable MRD with fixed-duration ibrutinib plus venetoclax in patients with CLL.

Riad Salem, MD, discusses data from 2 clinical trials comparing Y90 radioembolization vs conventional transarterial chemoembolization and drug-eluting bead transarterial chemoembolization for patients with HCC.

Anna Halpern, MD, presents study findings showing the addition of sorafenib to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone (CLAG-M) produces high rates of complete remission with MRD negativity in newly diagnosed AML and...

Leena Gandhi, MD, PhD, discusses the debate held at the 2022 Great Debates and Updates in Lung Cancer meeting, addressing first-line treatment options for patients with non-small cell lung cancer and PD-L1 > 50%.